Highlights from

European Respiratory Society

Congress 2018

Paris 15-19 September 2018

ICS: to use or not to use?

The role of ICS in COPD is an area of intense interest, said Dr Gary Ferguson (Pulmonary Research Institute of Southeast Michigan, USA) at the beginning of his lecture [16]. The recently updated GOLD guidelines recommend initiation of ICS treatment for patients with high exacerbation risk only [17], due to concerns over the risk:benefit ratio of chronic ICS use compared to other therapies. However, real-world studies have shown that ICS are prescribed across the spectrum of disease severity [18].

The benefits of ICS/LAMA/LABA triple therapy are not well studied in certain patient populations, such as patients who are considered to have a lower risk of exacerbations. Budesonide/glycopyrronium/formoterol metered-dose inhaler (MDI), formulated using an innovative co-suspension delivery technology, is a fixed-dose triple combination in development for patients with COPD. “KRONOS was partly a regulatory study to evaluate triple vs dual combination therapy”, stated Dr Ferguson. In symptomatic patients with moderate-to-severe COPD, mostly GOLD B, budesonide/glycopyrronium/formoterol (320/14.4/10 μg) MDI provided clinically meaningful improvements in lung function vs budesonide/formoterol, delivered as MDI or dry powder inhalers (DPI, Figure 3). This treatment effect was independent of exacerbation history.

Figure 3: Peak and trough FEV1 over 24 weeks in KRONOS study [16]

ERS 2018: Figure 3 Peak and trough

An important endpoint, according to Dr Ferguson, was the rate of moderate-to-severe COPD exacerbations over 24 weeks. Triple therapy resulted in significant, clinically meaningful reductions in exacerbation rates vs glycopyrronium/formoterol MDI, with numerical reductions vs budesonide/formoterol, delivered as MDI or DPI. There was a significant difference between triple and dual therapy with glycopyrronium/formoterol (rate ratio 0.48; 95% CI 0.37-0.64; P<0.0001). The time to first moderate-to-severe COPD exacerbation was also significantly different, again in comparison with glycopyrronium/formoterol (HR 0.593; 95% CI 0.37-0.64; P<0.0001, measured with Cox regression analysis). All treatments were well tolerated with no new or unexpected safety findings. The incidence of pneumonia was similar across treatment groups.

Favourable risk:benefit profile

According to Dr Ferguson, the favourable risk:benefit profile of budesonide/glycopyrronium/formoterol MDI challenges current recommendations for ICS use in COPD. “It raises a question of whether a broader patient population than just those with frequent exacerbations benefit from triple therapy. KRONOS supports the potential use of triple therapy in symptomatic patients with COPD who are not adequately controlled by dual therapy, irrespective of exacerbation risk.” The results of KRONOS were published online in The Lancet Respiratory Medicine [19].

  1. Ferguson GT, et al. Abstract OA1661, ERS 2018.
  2. GOLD COPD 2018, www.goldcopd.org
  3. Ding B, et al. Int J Chron Obstruct Pulmon Dis. 2017;12:1527-1537.
  4. Ferguson GT, et al. Lancet Respir Med. 2018, Sept 16.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.